Treatment of Restenosis and Stenosis with Dasatinib

a technology of dasatinib and restenosis, which is applied in the field of prevention and treatment of artery obstructive diseases, can solve the problems of renarrowing (restenosis) and limit the long-term efficacy of these revascularization therapies

Inactive Publication Date: 2007-05-31
H LEE MOFFITT CANCER CENT +1
View PDF11 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] The present invention provides a novel method for treating or inhibiting artery obstructive disease, such as restenosis (typically encountered after angioplasty and stenting procedures) and stenosis (typically encountered after coronary artery bypass surgery), in a subject by administering to the subject a therapeutically effective amount of dasatinib or a derivative thereof

Problems solved by technology

Unfortunately, renarrowing (restenosis) of the dilated artery occurs in 25-40% of patients within six months after these procedures, which requires repeat angioplasty or bypass surgery (Dangas and Kuepper, 2002; Michaels and Chatterjee, 2002).
Therefore, restenosis represents a major problem limiting the long-term efficacy of these revascularization therapies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of Restenosis and Stenosis with Dasatinib
  • Treatment of Restenosis and Stenosis with Dasatinib
  • Treatment of Restenosis and Stenosis with Dasatinib

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0061] BMS-354825 Inhibits PDGF-activated Signaling Pathways in VSMCs.

[0062] To determine if BMS-354825 could inhibit PDGFR activation in VSMCs, we treated serum-starved rat A10 cells with PDGF-BB (5 ng / ml) for 0-30 min in the presence or absence of 50 nM BMS-354825. Cell lysates were analyzed for activation of PDGFRβ, STAT3, Akt, and Erk2 by immunoblotting analyses (FIG. 1A). PDGFRβ is the predominant PDGFR subunit in VSMCs (Raines, 2004) and the only functional PDGFR subunit in A10 cells (Rao et al., 1997). STAT3, Akt, and Erk2 signaling pathways have been reported to mediate PDGF-induced cell migration and proliferation in VSMCs (Graf et al., 1997; Kim et al., 2005; Neeli et al., 2004; Shibata et al., 2003; Vantler et al., 2005; Zhan et al., 2003). PDGF treatment markedly increased PDGFRβ tyrosine phosphorylation, which was detectable at the earliest time point examined (1 min). BMS-354825 (50 nM) effectively blocked PDGF-stimulated PDGFRβ tyrosine phosphorylation at all time po...

example 2

[0065] Comparison of PDGFR Inhibition by BMS-354825 and Imatinib.

[0066] In addition to inhibiting Bcr-Abl and c-Kit, imatinib also inhibits PDGFR tyrosine kinase. To compare the inhibition of PDGFR in VSMCs by BMS-354825 and imatinib, A10 cells were pre-incubated with various concentrations of BMS-354825 or imatinib, stimulated with PDGF-BB, and activation of PDGFR, STAT3, Akt, and Erk2 were analyzed. FIG. 2A shows that PDGF-stimulated PDGFRβ tyrosine phosphorylation was completely blocked by 50 nM BMS-354825. In contrast, 5 μM imatinib was required to achieve the same level of PDGFR inhibition in parallel experiments. Similarly, complete inhibition of PDGF-stimulated Akt and Erk2 activation were observed in cells treated with 50 nM BMS-354825 but only with 5 μM imatinib, whereas decrease in STAT3 tyrosine phosphorylation appeared at lower concentrations of imatinib (FIG. 2A). Of note, inhibition of Akt by both BMS-354825 and imatinib was observed only at the highest drug concentra...

example 3

[0067] Inhibition of PDGFR in Human AoSMCs by BMS-354825.

[0068] To exclude the possibility that the potent inhibition of PDGFR by BMS-354825 is specific to rat VSMCs, we examined the effect of BMS-354825 in primary cultures of human AoSMCs. Human AoSMCs were pre-incubated with 0-50 nM BMS-354825 and then stimulated with PDGF-BB (5 ng / ml, 5 min). PDGFR tyrosine phosphorylation and activation of STAT3, Akt, and Erk2 were analyzed. PDGF markedly induced PDGFR tyrosine phosphorylation in human AoSMCs (FIG. 3). Similar to that observed in A10 cells, the PDGF-stimulated PDGFR tyrosine phosphorylation was completely blocked by 50 nM BMS-354825.

[0069] The primary culture of human AoSMCs appeared to have an elevated level of active STAT3 in the absence of PDGF stimulation (FIG. 3). Nevertheless, STAT3 was further activated by PDGF, which was blocked by BMS-354825. BMS-354825, however, was unable to reduce the active STAT3 to a level below the basal activation state in human AoSMCs. Similar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

A method for treating or inhibiting artery obstructive disease, such as restenosis after angioplasty and stenting procedures and stenosis after coronary artery bypass surgery, in a subject by administering to the subject a therapeutically effective amount of dasatinib or a derivative thereof Also provided are drug-eluting medical devices, including stents, having a therapeutically effective amount of dasatinib.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to currently pending U.S. Provisional Patent Application 60 / 728,673, entitled, “Potent Inhibition of Platelet-Derived Growth Factor-Induced Responses in Vascular Smooth Muscle Cells By BMS-354825”, filed Oct. 20, 2005, the contents of which are herein incorporated by reference.FIELD OF INVENTION [0002] This invention relates to prevention and treatment of artery obstructive diseases. More specifically, this invention relates to methods for treating or preventing restenosis and stenosis in humans using dasatinib. BACKGROUND OF THE INVENTION [0003] Balloon angioplasty and stenting (percutaneous coronary interventions with or without the use of stents) are widely used procedures for coronary artery disease. Unfortunately, renarrowing (restenosis) of the dilated artery occurs in 25-40% of patients within six months after these procedures, which requires repeat angioplasty or bypass surgery (Dangas and Kueppe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/506
CPCA61K31/506
Inventor WU, JIECHEN, ZHENGMINGBHALLA, KAPIL
Owner H LEE MOFFITT CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap